<DOC>
	<DOCNO>NCT02052115</DOCNO>
	<brief_summary>Overweight physically inactive breast cancer survivor increase risk breast cancer recurrence mortality . Cancer treatment-related change likely mediate weight loss exercise success include long term effect fatigue , psychological distress impaired executive ( cognitive ) function . This study explore variability breast cancer survivor respond behavioral weight loss intervention . The primary objective include determine degree success behavioral weight loss intervention overweight breast cancer survivor explain measure executive function measure task performance 6 12 month associate brain function imaging ( fMRI ) , collect baseline only.Additionally , study design determine degree select measure cancer-related symptom account variance success breast cancer survivor 6 12 month follow entry behavioral weight loss exercise intervention .</brief_summary>
	<brief_title>Behavioral Weight Loss Exercise After Treatment ( BEAT )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Breast cancer diagnosis Received surgery +/ chemotherapy +/ radiation treatment Stage I , II III breast cancer . Ongoing treatment monoclonal antibody and/or antiestrogen therapy acceptable Completion initial therapy 6 week prior study initiation BMI 2745 kg/m^2 Prior diagnosis malignancy nonmelanoma skin cancer ( i.e . prior nonmelanoma skin cancer exclusion criterion ) Medical condition limit food choice celiac sprue inflammatory bowel disease Inability walk flat ground ( treadmill ) 2.5 mph 5 minute Age &lt; 21 &gt; 70 Presence body metal Psychotic central nervous system impairment would limit compliance study requirement , include dementia Evidence metastatic disease Symptomatic heart disease ( chest pain equivalent activity ) Exercise limit pulmonary disease need oxygen exercise Individuals take mood stabilize medication include : Lithium , valproic acid , also call divalproex sodium ( Depakote ) , carbamazepine ( Tegretol ) , lamotrigine ( Lamictal ) , oxcarbazepine ( Trileptal ) , olanzapine ( Zyprexa ) , aripiprazole ( Abilify ) , risperidone ( Risperdal ) , ziprasidone ( Geodon ) , clozapine ( clorazil ) Participants active neurologic disorder affect central nervous system , include seizure , Parkinson 's disease Weight loss &gt; 10 lb previous 6 month Participation &gt; 150 minute moderate intensity activity self report , unless activity level accelerometer less 150 minute moderate intensity activity</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>exercise</keyword>
	<keyword>weight loss</keyword>
	<keyword>executive function</keyword>
	<keyword>breast cancer survivor</keyword>
</DOC>